Mandate

Vinge advises EQT VI on acquisition of Atos Medical

July 22, 2011

Vinge is advising funds managed by EQT VI Limited in connection with the acquisition of Atos Medical from funds managed by Nordic Capital V Limited (94.6%) and board directors and employees (5.4%). Atos supplies products to the ear, nose and throat (“ENT”) medical segment and is the market leader in voice prosthesis. The acquisition is subject to customary conditions.

The Vinge team included partners Christina Kokko and Johan Göthberg and associates Malin Helgesen, Peter Sundgren, Paul Dali and Anna-Sofia Nilsson Prevell (M&A), partner Maria-Pia Hope and associates Albert Wållgren and Andreas Malmberg (banking & finance), and partner Marcus Glader and associate Peter Alstergren (EU & competition).

Related

Vinge represents Sedana Medical AB in the acquisition of Innovatif Cekal

Vinge has represented Sedana Medical AB (publ) in connection with the acquisition of Innovatif Cekal. Innovatif Cekal, based in Klang near Kuala Lumpur, Malaysia, is a manufacturer of medical devices. This acquisition enhances Sedana Medical's control over its supply chain and improves profitability through reduced cost of goods.
January 22, 2025

Vinge advises Infranity in connection with the acquisition of Nordic Re-Finance AB

Vinge has advised Infranity, a private equity firm specializing in infrastructure investments, in connection with its acquisition of a majority stake in Nordic Re-Finance AB, a Scandinavian locomotives lessor. The acquisition brings ambitious development plans for Nordic Re-Finance AB, including expansion into new geographical areas.
January 20, 2025

Vinge advises Platzer in conjunction with the sale of a school property in Gothenburg

Vinge has advised Platzer Fastigheter AB in connection with the sale of a school property situated in Södra Änggården, Gothenburg. The property, which was sold as a corporate transaction, has a value of SEK 552 million. The sale is part of Platzer's strategy to develop and optimise its property portfolio.
January 17, 2025